Blueshift Asset Management LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Blueshift Asset Management LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,021 shares of the biopharmaceutical company’s stock, valued at approximately $573,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new position in Halozyme Therapeutics in the first quarter valued at approximately $32,000. SVB Wealth LLC purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter worth approximately $33,000. Employees Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $34,000. Brooklyn Investment Group grew its position in shares of Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 670 shares during the last quarter. Finally, Asset Management One Co. Ltd. acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth $98,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 16,569 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48. Following the completion of the sale, the chief executive officer owned 708,719 shares of the company’s stock, valued at approximately $48,844,913.48. This trade represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 829 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $71.60, for a total transaction of $59,356.40. Following the sale, the director owned 42,123 shares in the company, valued at $3,016,006.80. The trade was a 1.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 103,625 shares of company stock worth $7,446,727 over the last three months. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Trading Down 2.3%

Shares of Halozyme Therapeutics stock opened at $66.54 on Wednesday. Halozyme Therapeutics, Inc. has a 52-week low of $46.26 and a 52-week high of $79.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The company’s 50-day simple moving average is $68.83 and its 200-day simple moving average is $64.20. The firm has a market cap of $7.82 billion, a price-to-earnings ratio of 15.23, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. During the same quarter last year, the firm earned $1.27 earnings per share. The firm’s revenue was up 22.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research reports. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price on the stock in a research report on Tuesday, October 14th. Morgan Stanley lowered their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Friday. Benchmark increased their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Finally, JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $75.10.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.